M&T Bank Corp Has $2.16 Million Stock Position in Ralliant Corporation $RAL

Key Points

• M&T Bank Corp boosted its stake in Ralliant by 464.6% in Q4 to 42,359 shares worth $2.16M, while large holders like Vanguard (14.59M shares) and other institutions (Phocas, Allspring) also materially increased positions.
• Ralliant beat Q4 estimates with $0.69 EPS and $554.6M revenue, issued FY 2026 guidance of 2.22–2.42 EPS (analysts expect 2.37), and trades around $43.85 with a consensus price target of $50.50.
• Insiders acquired 8,145 shares in the past three months (notable buys by Director Kate Mitchell and SVP Amir Kazmi), and analysts collectively rate the stock a “Moderate Buy” (7 Buys, 4 Holds, 1 Sell).

M&T Bank Corp raised its holdings in Ralliant Corporation (NYSE:RAL - Free Report) by 464.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 42,359 shares of the company's stock after acquiring an additional 34,857 shares during the quarter. M&T Bank Corp's holdings in Ralliant were worth $2,156,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RAL. Phocas Financial Corp. increased its position in shares of Ralliant by 81.2% during the fourth quarter. Phocas Financial Corp. now owns 157,116 shares of the company's stock worth $7,999,000 after buying an additional 70,403 shares during the period. Vanguard Group Inc. increased its position in shares of Ralliant by 10.7% during the third quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company's stock worth $637,995,000 after buying an additional 1,415,327 shares during the period. Welch & Forbes LLC acquired a new stake in shares of Ralliant during the third quarter worth $854,000. SG Capital Management LLC acquired a new stake in shares of Ralliant during the third quarter worth $8,139,000. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Ralliant by 5,269.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 317,038 shares of the company's stock worth $14,000,000 after buying an additional 311,134 shares during the period.

Insiders Place Their Bets

In other Ralliant news, Director Kate Mitchell acquired 2,350 shares of the company's stock in a transaction on Tuesday, February 10th. The shares were purchased at an average cost of $42.48 per share, with a total value of $99,828.00. Following the completion of the purchase, the director owned 8,411 shares of the company's stock, valued at approximately $357,299.28. This represents a 38.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Amir A. Kazmi acquired 2,545 shares of the company's stock in a transaction on Friday, February 6th. The stock was acquired at an average cost of $39.27 per share, for a total transaction of $99,942.15. Following the completion of the purchase, the senior vice president directly owned 39,699 shares of the company's stock, valued at approximately $1,558,979.73. This represents a 6.85% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 8,145 shares of company stock valued at $332,233.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RAL. Vertical Research upgraded shares of Ralliant from a "hold" rating to a "buy" rating and set a $45.00 price objective for the company in a research report on Friday, February 6th. Royal Bank Of Canada decreased their price objective on shares of Ralliant from $52.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 6th. Morgan Stanley reiterated an "overweight" rating and set a $45.00 price objective on shares of Ralliant in a research report on Friday, February 6th. Barclays decreased their price objective on shares of Ralliant from $60.00 to $52.00 and set an "overweight" rating for the company in a research report on Monday, February 9th. Finally, Zacks Research upgraded shares of Ralliant from a "strong sell" rating to a "hold" rating in a research report on Monday, April 13th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $50.50.

Ralliant Trading Down 1.2%

NYSE:RAL opened at $43.85 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $4.91 billion and a price-to-earnings ratio of 22.37. The firm has a fifty day simple moving average of $44.07 and a two-hundred day simple moving average of $46.89. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $57.02.

Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS. Analysts expect that Ralliant Corporation will post 2.37 EPS for the current fiscal year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 23rd. Shareholders of record on Monday, March 9th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Monday, March 9th. Ralliant's dividend payout ratio (DPR) is presently 10.20%.

Ralliant Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.